A Pharmacokinetic Study of Tulisokibart Administered Subcutaneously Via Autoinjector or Syringe in Healthy Adult Participants
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Tulisokibart (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 18 Feb 2025 Status changed from active, no longer recruiting to completed.
- 11 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2024 Status changed from not yet recruiting to recruiting.